Compare RMCF & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMCF | BIVI |
|---|---|---|
| Founded | 1981 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9M | 12.4M |
| IPO Year | 2024 | 2013 |
| Metric | RMCF | BIVI |
|---|---|---|
| Price | $0.73 | $1.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.26 |
| AVG Volume (30 Days) | 24.0K | ★ 811.3K |
| Earning Date | 10-19-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 34.88 | ★ 74.83 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,432,352.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.66 | $0.82 |
| 52 Week High | $2.99 | $3.79 |
| Indicator | RMCF | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 34.56 | 41.73 |
| Support Level | $0.66 | $1.15 |
| Resistance Level | $1.19 | $1.47 |
| Average True Range (ATR) | 0.06 | 0.22 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 2.61 | 3.54 |
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The company prepares numerous products, including caramel apples in the store. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, and Others. The company derives maximum revenue through manufacturing activities. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.